AVR Stock Forecast & Price Target

Anteris Technologies Glb is viewed positively because DurAVR’s single-piece, biomimetic design appears structurally differentiated from competing TAVR valves, with physician-led feedback and head-to-head PARADIGM positioning supporting a credible path to clinical and commercial disruption. The company’s data package is compelling, including ~1,054-patient PARADIGM design, 130+ advanced EFS/EMBARK patients, low mean gradients in the low 8s in small annuli versus low-to-mid teens for competitors, and Cleveland Clinic data showing just 3% PPM versus 40%+ for peers. Financially, the thesis is reinforced by $260.9 million of cash, accelerating 2Q26 R&D to $23.4 million, expanding enrollment into the United States and France, and the expectation of ~181% 2026-2030 revenue CAGR versus 18% for peers.

Anteris Technologies Glb is exposed to substantial downside risk because its DurAVR strategy still depends on PARADIGM trial outcomes that could fall below expectations and on a regulatory path that may take longer than it is capitalized to handle for PMA approval. The company has also incurred significant operating losses and negative cash flow, raising the risk that expenses could grow to a level of inoperability before commercialization meaningfully improves the business. In addition, DurAVR lacks a proven marketing or sales strategy, which could slow adoption by the medical community and weaken the commercial case for a product whose success is still unproven.